At Kedrion Biopharma, our mission is to enhance lives through our work in the field of rare and ultra-rare diseases. We are committed to collecting plasma and producing plasma-derived therapies that treat and prevent rare and debilitating conditions such as Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization.

Fondazione Telethon is an Italian non-profit organization committed to advancing research on rare genetic diseases. For over 35 years, we have supported high-impact science aimed at developing innovative treatments and improving the lives of people affected by these conditions.

At Sobi North America, we are inspired by a single vision – to be recognized as a global leader in providing innovative medicines that transform the lives of people with rare and debilitating diseases.

GC Biopharma, the top pharmaceutical manufacturer of plasma products in Asia, is among the largest worldwide, distributing to more than 50 countries.

We are a global, values-based, R&D-driven biopharmaceutical leader with a large U.S. presence. We aim to discover and deliver lifetransforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Octapharma is the largest privately owned and independent plasma fractionator in the world. Our medicines are high-quality human proteins sourced from human plasma and human cell lines. We develop and manufacture medicines for patients in three therapeutic areas: hematology, immunotherapy and critical care.